Bruce A. Keyt

12.4k citations

79 papers · 9.9k indexed · 5 hit papers · h-index 31

Impact in

Ophthalmology top 0.1%
- Retinal Diseases and Treatments
- Glaucoma and retinal disorders
- Retinal and Optic Conditions
Hematology top 0.5%
- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms

Papers in

Cancer Research 23
- Protease and Inhibitor Mechanisms 16
- Cancer, Hypoxia, and Metabolism 8
Hematology 16
- Blood Coagulation and Thrombosis Mechanisms 14

Co-authors: Napoleone Ferrara Hans-Peter Gerber Minhong Yan Joe Kowalski Vishva M. Dixit Paul G. Arrigg Robert L. Avery Louis R. Pasquale
Journals: Cancer Research (13 papers)Blood (9 papers)Journal of Biological Chemistry (8 papers)Thrombosis and Haemostasis (4 papers)Nature (2 papers)
Partner nations: United States Germany Australia

In The Last Decade

Bruce A. Keyt

72 papers receiving 9.4k citations

Hit Papers

5 papers align trajectories log scale

Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway 1998 · 1.7k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1998 Journal of Biological Chemistry
1996 Journal of Biological Chemistry
1994 New England Journal of Medicine
1984 Nature
1984 Nature

Peers

Countries citing papers authored by Bruce A. Keyt

Since Specialization

Citations

This map shows the geographic impact of Bruce A. Keyt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce A. Keyt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce A. Keyt more than expected).

Fields of papers citing papers by Bruce A. Keyt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce A. Keyt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce A. Keyt. The network helps show where Bruce A. Keyt may publish in the future.

Co-authors

The 25 scholars most cited alongside Bruce A. Keyt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bruce A. Keyt Line = papers co-authored together Bruce A. Keyt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells Cancer Immunology Research ·Mélanie Desbois, Thierry Giffon, André Niciporenco Neto, Hari-Hara Surya Kumar Potula, R. Verdi, Kevin C. Hart, Daniel Santos, Jinglie Wang, Kathryn Logronio, Janice Kover, Dean Ng, Avneesh K. Saini, Hong-Soo Jung, Bruce A. Keyt, Angus M. Sinclair, Maya F. Kotturi	2025	1
2	An engineered IgM antibody targeting CD20 has enhanced complement-dependent cytotoxicity compared with an IgG Experimental Hematology ·Kevin C. Hart, Paul R. Hinton, A. Ragas, А. М. Шошина, Sandra M. Schneider, Maya F. Kotturi, Ramesh Baliga, Bruce A. Keyt	2025	0
3	Abstract 1899: Novel combinations of aplitabart, a DR5 agonist IgM antibody, with ADCs or chemotherapeutic agents lead to robust anti-tumor responses in solid tumor models Cancer Research ·Mélanie Desbois, Jinglie Wang, Kevin C. Hart, Hari-Hara Surya Kumar Potula, André Niciporenco Neto, Thomas J. Matthew, Maya K. Leabman, Sanela Bilic, Genevive Hernandez, Eric W. Humke, Albert F. Candia, Bruce A. Keyt, Angus M. Sinclair, Maya F. Kotturi, Hong-Soo Jung	2024	1
4	Abstract 2959: Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells though complement and T cell dependent mechanisms Cancer Research ·Keyu Li, Pati Hariyose, Ralph J. Ferrara, André Niciporenco Neto, Sun Cheng-nan, R. Ennaoui, Liqin Liu, Lynnea D. Harris, Daniel Santos, Kevin C. Hart, Dean Ng, Paul R. Hinton, И. А. Годдард, Thomas Manley, Maya F. Kotturi, Stephen F. Carroll, Angus M. Sinclair, Bruce A. Keyt	2023	1
5	Combination of Imvotamab and Loncastuximab Tesirine Shows Enhanced Anti‐Tumor Activity in a Preclinical Model of Non‐Hodgkin’s Lymphoma Hematological Oncology ·Kathryn Logronio, 陈未, Miho Oyasu, André Niciporenco Neto, Jiang Lu-nin, Genevive Hernandez, Thomas Manley, Angus M. Sinclair, Stephen F. Carroll, Albert F. Candia, Bruce A. Keyt, Grace Jabali	2023	1
6	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants BioDrugs ·William R. Strohl, Zhiqiang Ku, Zhiqiang An, Stephen F. Carroll, Bruce A. Keyt, Wei-Zhi Hu	2022	28
7	A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies Blood ·Elizabeth Budde, Ajay K. Gopal, Won Seog Kim, Ian W. Flinn, Chan Y. Cheah, Loretta J. Nastoupil, Matthew J. Matasar, Catherine Diefenbach, Gareth P. Gregory, L. Chengyu, Hui-Yin Shaw, Maya K. Leabman, Genevive Hernandez, Asa Wheelock, Bruce A. Keyt, Daniel Chen, Philippe Armand	2021	22
8	Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199 Molecular Cancer Therapeutics ·Hong-Soo Jung, B. Helmer, Ling Wang, Thomas J. Matthew, Jinglie Wang, Avneesh K. Saini, Maya F. Kotturi, Genevive Hernandez, Eric W. Humke, Marvin S. Peterson, Angus M. Sinclair, Bruce A. Keyt	2021	30
9	Abstract 3050: Multimeric IgM antibodies targeting DR5 are potent and rapid inducers of tumor cell apoptosis and cell death in vitro and in vivo Cancer Research ·Béatrice Wang, B. Helmer, Ling Wang, Avneesh K. Saini, Ramesh Baliga, Angus M. Sinclair, Bruce A. Keyt	2019	2
10	Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients The Journal of Immunology ·Ellen J. Collarini, MP Mendoza, Orit Foord, Minha Park, Gizette Sperinde, Chenzhao Yuan, William Harriman, Stephen F. Carroll, Karen Badikyan, Larry J. Anderson, Ralph A. Tripp, Edward E. Walsh, Bruce A. Keyt, Lawrence M. Kauvar	2009	79
11	Solution structure of the heparin-binding domain of vascular endothelial growth factor Structure ·Wayne J. Fairbrother, Mark Champe, Hans W. Christinger, Bruce A. Keyt, Melissa A. Starovasnik	1998	160
12	Role of the heparin binding domain in the clearance and localization of vascular endothelial growth factor Journal of the American College of Cardiology ·Hajar Haddouch, Jūratė Terepaitė, Bruce A. Keyt, A. M. Ryan, R.P. Kisoka, Ben‐Quan Shen, Thomas F. Zioncheck	1998	1
13	Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway Journal of Biological Chemistry ·Hans-Peter Gerber, Kai-Oliver Burmann, Joe Kowalski, Minhong Yan, Bruce A. Keyt, Vishva M. Dixit, Napoleone Ferrara Hit paper breakdown →	1998	1670
14	¹H, ¹³C, and ¹⁵N backbone assignment and secondary structure of the receptor‐binding domain of vascular endothelial growth factor Protein Science ·Wayne J. Fairbrother, Mark Champe, Hans W. Christinger, Bruce A. Keyt, Melissa A. Starovasnik	1997	16
15	The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency Journal of Biological Chemistry ·Bruce A. Keyt, Lea T. Berleau, Hung Van Nguyen, Helen Chen, Henry Heinsohn, Richard Vandlen, Napoleone Ferrara Hit paper breakdown →	1996	507
16	Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. Journal of Clinical Investigation ·Edi Brogi, Gina C. Schatteman, Ta‐Peng Wu, Eunyoung Kim, Lyuba Varticovski, Bruce A. Keyt, Jeffrey M. Isner	1996	288
17	Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors Journal of Biological Chemistry ·Bruce A. Keyt, Hung Van Nguyen, Lea T. Berleau, Carlos M. Duarte, Jeanie Park, Helen Chen, Napoleone Ferrara	1996	418
18	Crystallization of the receptor binding domain of vascular endothelial growth factor Proteins Structure Function and Bioinformatics ·Hans W. Christinger, Yves A. Muller, Lea T. Berleau, Bruce A. Keyt, Brian C. Cunningham, Napoleone Ferrara, Abraham M. de Vos	1996	46
19	Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders New England Journal of Medicine ·Lloyd Paul Aiello, Robert L. Avery, Paul G. Arrigg, Bruce A. Keyt, Henry Jampel, Sabera T. Shah, Louis R. Pasquale, Hagen Thieme, Mami Iwamoto, John E. Park, Van Hung Nguyen, Lloyd M. Aiello, Napoleone Ferrara, George L. King Hit paper breakdown →	1994	3027
20	Radioiodination of the active site of tissue plasminogen activator: A method for radiolabeling serine proteases with tyrosylprolylarginyl chloromethyl ketone Analytical Biochemistry ·Bruce A. Keyt, Lea T. Berleau, Hung Van Nguyen, William F. Bennett	1992	9

About Bruce A. Keyt

Bruce A. Keyt is a scholar working on Cancer Research, Hematology, Radiology, Nuclear Medicine and Imaging, Immunology and Allergy and Immunology, having authored 79 papers that have together received 9.9k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (31 papers), Angiogenesis and VEGF in Cancer (17 papers), Protease and Inhibitor Mechanisms (16 papers), Blood Coagulation and Thrombosis Mechanisms (14 papers), CAR-T cell therapy research (14 papers), Glycosylation and Glycoproteins Research (10 papers), Blood properties and coagulation (9 papers) and Cancer, Hypoxia, and Metabolism (8 papers). The work is most often cited by research in Ophthalmology (2.5k citations), Hematology (1.7k citations), Cancer Research (1.6k citations), Radiology, Nuclear Medicine and Imaging (2.1k citations) and Immunology and Allergy (461 citations). Bruce A. Keyt has collaborated with scholars based in United States, Germany and Australia. Frequent co-authors include Napoleone Ferrara, Hans-Peter Gerber, Minhong Yan, Joe Kowalski, Vishva M. Dixit, Paul G. Arrigg, Robert L. Avery, Louis R. Pasquale, Lloyd Paul Aiello and Henry Jampel. Their work appears in journals such as Cancer Research, Blood, Journal of Biological Chemistry, Thrombosis and Haemostasis and Nature.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact